113 related articles for article (PubMed ID: 28013118)
1. Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction.
Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
Clin Gastroenterol Hepatol; 2017 May; 15(5):787-788. PubMed ID: 28013118
[No Abstract] [Full Text] [Related]
2. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
Ahmed AM; Doheim MF; Mattar OM; Sherif NA; Truong DH; Hoa PTL; Hirayama K; Huy NT
J Med Virol; 2018 May; 90(5):907-918. PubMed ID: 28892235
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
Nakamura Y; Imamura M; Kawakami Y; Teraoka Y; Daijo K; Honda F; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Chayama K
J Med Virol; 2017 Apr; 89(4):665-671. PubMed ID: 27602542
[TBL] [Abstract][Full Text] [Related]
5. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
[TBL] [Abstract][Full Text] [Related]
6. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyazaki R; Miyagi K
Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
[TBL] [Abstract][Full Text] [Related]
7. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
Suda G; Furusyo N; Toyoda H; Kawakami Y; Ikeda H; Suzuki M; Arataki K; Mori N; Tsuji K; Katamura Y; Takaguchi K; Ishikawa T; Tsuji K; Shimada N; Hiraoka A; Yamsaki S; Nakai M; Sho T; Morikawa K; Ogawa K; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kato K; Ueno Y; Iio E; Tanaka Y; Kurosaki M; Kumada T; Chayama K; Sakamoto N
J Gastroenterol; 2018 Jan; 53(1):119-128. PubMed ID: 28560477
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
Kawakami Y; Imamura M; Ikeda H; Suzuki M; Arataki K; Moriishi M; Mori N; Kokoroishi K; Katamura Y; Ezaki T; Ueno T; Ide K; Masaki T; Ohdan H; Chayama K
J Viral Hepat; 2016 Nov; 23(11):850-856. PubMed ID: 27346670
[TBL] [Abstract][Full Text] [Related]
10. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
Kato K; Shimada N; Atsukawa M; Abe H; Itokawa N; Matsumoto Y; Agata R; Tsubota A
PLoS One; 2019; 14(7):e0219022. PubMed ID: 31291311
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
J Gastroenterol Hepatol; 2017 Nov; 32(11):1879-1886. PubMed ID: 28258705
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
Hassanein T; Sims KD; Bennett M; Gitlin N; Lawitz E; Nguyen T; Webster L; Younossi Z; Schwartz H; Thuluvath PJ; Zhou H; Rege B; McPhee F; Zhou N; Wind-Rotolo M; Chung E; Griffies A; Grasela DM; Gardiner DF
J Hepatol; 2015 May; 62(5):1204-6. PubMed ID: 25559328
[No Abstract] [Full Text] [Related]
15. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
Thiam A; Conway B
Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Poordad F; Sievert W; Mollison L; Bennett M; Tse E; Bräu N; Levin J; Sepe T; Lee SS; Angus P; Conway B; Pol S; Boyer N; Bronowicki JP; Jacobson I; Muir AJ; Reddy KR; Tam E; Ortiz-Lasanta G; de Lédinghen V; Sulkowski M; Boparai N; McPhee F; Hughes E; Swenson ES; Yin PD;
JAMA; 2015 May; 313(17):1728-35. PubMed ID: 25942723
[TBL] [Abstract][Full Text] [Related]
17. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
[TBL] [Abstract][Full Text] [Related]
18. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
Zeuli JD; Adie SK; Rizza SA; Temesgen Z
Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
[TBL] [Abstract][Full Text] [Related]
19. The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.
Taki S; Tamai H; Ida Y; Shingaki N; Kawashima A; Shimizu R; Moribata K; Maekita T; Iguchi M; Kato J; Nakao T; Kitano M
Gut Liver; 2018 Jan; 12(1):86-93. PubMed ID: 28798288
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
